Research Analysts Set Expectations for AXSM FY2024 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Zacks Research decreased their FY2024 earnings per share estimates for Axsome Therapeutics in a report released on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the company will post earnings of ($5.42) per share for the year, down from their previous estimate of ($5.32). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.60) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q4 2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($1.71) EPS, Q2 2025 earnings at ($1.60) EPS, Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.77) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at ($0.67) EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. During the same period last year, the firm posted ($1.32) earnings per share.

Other equities analysts also recently issued research reports about the company. Robert W. Baird lifted their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Royal Bank of Canada boosted their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Mizuho cut their price objective on shares of Axsome Therapeutics from $124.00 to $122.00 and set an "outperform" rating for the company in a research report on Tuesday, December 31st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $121.00 target price on shares of Axsome Therapeutics in a report on Thursday, December 12th. Finally, HC Wainwright restated a "buy" rating on shares of Axsome Therapeutics in a report on Tuesday, December 31st. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $127.29.

Axsome Therapeutics Price Performance

AXSM traded down $1.21 during trading on Thursday, reaching $82.57. The company's stock had a trading volume of 655,013 shares, compared to its average volume of 815,843. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The firm has a fifty day simple moving average of $92.48 and a two-hundred day simple moving average of $89.04. The company has a market cap of $4.00 billion, a price-to-earnings ratio of -12.64 and a beta of 1.04. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $105.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Arizona State Retirement System boosted its stake in shares of Axsome Therapeutics by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company's stock valued at $695,000 after buying an additional 177 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after acquiring an additional 318 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Axsome Therapeutics in the second quarter worth approximately $27,000. WCM Investment Management LLC grew its holdings in Axsome Therapeutics by 0.3% during the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company's stock worth $10,191,000 after acquiring an additional 347 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Axsome Therapeutics by 0.3% in the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company's stock valued at $11,964,000 after purchasing an additional 421 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.